Table 1.
Patient characteristics.
| REG group | p value* | FTD/TPI group | p value* | |||
|---|---|---|---|---|---|---|
| Right (n = 60) | Left (n = 163) | Right (n = 62) | Left (n = 265) | |||
| Age, years | ||||||
| Median (IQR) | 65 [58–71] | 64 [55–71] | 0.30 | 65 [59–72] | 64 [55–70] | 0.17 |
| ≥ 65, n (%) | 31 (51.7) | 76 (46.6) | 0.55 | 33 (53.2) | 123 (46.4) | 0.40 |
| Sex, n (%) | 0.17 | 0.89 | ||||
| Male | 29 (48.3) | 97 (59.5) | 38 (61.3) | 159 (60.0) | ||
| Female | 31 (51.7) | 66 (40.5) | 24 (38.7) | 106 (40.0) | ||
| BMI, n (%) | 0.025 | 0.046 | ||||
| ≥ 18.5 | 47 (78.3) | 147 (90.2) | 45 (72.6) | 222 (83.8) | ||
| ECOG PS, n (%) | 0.086 | 0.41 | ||||
| PS0 or 1 | 56 (93.3) | 160 (98.2) | 56 (90.3) | 248 (93.6) | ||
| PS2 | 4 (6.7) | 3 (1.8) | 6 (9.7) | 17 (6.4) | ||
| Surgery on primary tumor, n (%) | 0.20 | 0.31 | ||||
| Yes | 51 (85.0) | 125 (76.7) | 45 (72.6) | 210 (79.2) | ||
| Histological grade, n (%) | 0.01 | 0.35 | ||||
| Well/mod | 48 (80.0) | 149 (91.4) | 55 (88.7) | 242 (91.3) | ||
| Others | 10 (16.7) | 7 (4.3) | 3 (4.8) | 16 (6.0) | ||
| Missing | 2 (3.3) | 7 (4.3) | 4 (6.5) | 7 (2.6) | ||
| RAS status, n (%) | < 0.001 | 0.013 | ||||
| Mutant | 42 (70.0) | 67 (41.1) | 37 (59.7) | 124 (46.8) | ||
| Missing | 0 (0.0) | 6 (3.7) | 3 (4.8) | 3 (1.1) | ||
| Metastasis, n (%) | ||||||
| Liver | 40 (66.7) | 101 (62.0) | 0.54 | 40 (64.5) | 161 (60.8) | 0.66 |
| Lung | 29 (48.3) | 51 (31.3) | 0.027 | 28 (45.2) | 79 (29.8) | 0.024 |
| Lymph node | 26 (43.3) | 68 (41.7) | 0.88 | 21 (33.9) | 122 (46.0) | 0.089 |
| Peritoneum | 15 (25.0) | 20 (12.3) | 0.036 | 26 (41.9) | 41 (15.5) | < 0.001 |
| Number of metastatic organ site(s), n (%) | 0.17 | |||||
| ≥ 3 | 11 (18.3) | 46 (28.2) | 25 (40.3) | 103 (38.9) | 0.89 | |
| Duration from initiation of 1st line chemotherapy, n (%) | 0.13 | 0.078 | ||||
| ≥ 18 months | 39 (65.0) | 124 (76.1) | 40 (64.5) | 201 (75.8) | ||
| Prior regimens, n (%) | 0.024 | < 0.001 | ||||
| ≥ 3 | 21 (35.0) | 85 (52.1) | 17 (27.4) | 147 (55.5) | ||
*The p values were calculated using the Mann-Whitney U test for continuous variable and Fisher’s exact probability test for categorical variables.
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; RAS, rat sarcoma; REG, regorafenib; FTD/TPI, trifluridine/tipiracil.